CD2 Antibody (299812) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # FAB18561H
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry, Immunocytochemistry
Label
HRP
Antibody Source
Monoclonal Mouse IgG1 Clone # 299812
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human CD2
Lys25-Asp209
Accession # P06729
Lys25-Asp209
Accession # P06729
Specificity
Detects recombinant human CD2 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse (rm) CD2 or rmCD2F-10 is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for CD2 Antibody (299812) [HRP]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD2
The CD2-CD58 interaction has been shown to play a role in anti-tumor immune response, where reduced CD58 signaling is associated with immune escape of tumor cells in various hematological and lymphoid malignancies, but restoration of the signal promotes an anti-tumor response (2,5). Additionally, following cytomegalovirus (CMV) infection, CD2's binding to upregulated CD58 on CMV-infected cells is crucial for the activation and function of adaptive NK cells in the anti-viral response (2). In contrast, in situations where there is an increase in T cell and NK cell activation, like various autoimmune disorders or following organ transplant, costimulatory blockade of CD2-CD58 may be a potential therapeutic treatment approach (1). Mouse and rat xenograft models have shown that blocking the CD2 using anti-CD2 monoclonal antibodies contributes to graft survival and protects against lymphocyte infiltration and inflammatory damage (2).
References
1. Binder C, Cvetkovski F, Sellberg F, et al. CD2 Immunobiology. Front Immunol. 2020;11:1090. https://doi.org/10.3389/fimmu.2020.01090
2. Zhang Y, Liu Q, Yang S, Liao Q. CD58 Immunobiology at a Glance. Front Immunol. 2021;12:705260. https://doi.org/10.3389/fimmu.2021.705260
3. Uniprot (P06729)
4. van der Merwe PA. A subtle role for CD2 in T cell antigen recognition. J Exp Med. 1999;190(10):1371-1374. https://doi.org/10.1084/jem.190.10.1371
5. Nishikori M, Kitawaki T, Tashima M, Shimazu Y, Mori M, et al. Diminished CD2 Expression in T cells Permits Tumor Immune Escape. J Clin Cell Immunol. 2016;7:406. https://doi.org/10.4172/2155-9899.1000406
Alternate Names
CD2, LFA-2, T11
Gene Symbol
CD2
Additional CD2 Products
Product Documents for CD2 Antibody (299812) [HRP]
Product Specific Notices for CD2 Antibody (299812) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...